News & Updates
Filter by Specialty:
Long-term secukinumab safe, effective in kids with plaque psoriasis
Long-term treatment with secukinumab, either at low or high dose, results in sustained efficacy and better health-related quality of life up to 4 years in children and adolescents with moderate-to-severe chronic plaque psoriasis, as shown in a phase III study presented at EADV 2024.
Long-term secukinumab safe, effective in kids with plaque psoriasis
11 Oct 2024
Clozapine-treated patients with schizophrenia at risk for ileus, pneumonia
Ileus and pneumonia occur more frequently than previously reported among individuals with schizophrenia treated with clozapine, reveals a recent study, noting that such conditions also contribute to increased mortality.
Clozapine-treated patients with schizophrenia at risk for ileus, pneumonia
10 Oct 2024
Hormone therapy prevents relapse in women with schizophrenia
The use of menopausal hormone therapy (MHT) can provide protection against psychosis relapse among women of menopausal age with schizophrenia or schizoaffective disorder (SSD), a study has shown.
Hormone therapy prevents relapse in women with schizophrenia
10 Oct 2024
NIAGARA interim data support perioperative durvalumab for MIBC
In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).
NIAGARA interim data support perioperative durvalumab for MIBC
10 Oct 2024
KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).
